Development of a Patient Reported Measure of Experimental Transplants with HIV and Ethics in the United States (PROMETHEUS)
Journal of Patient-Reported Outcomes volume 5, Article number: 28 (2021)
Transplantation of HIV-positive (HIV+) donor organs for HIV+ recipients (HIV D+/R+) is now being performed as research in the United States, but raises ethical concerns. While patient-reported outcome measures are increasingly used to evaluate clinical interventions, there is no published measure to aptly capture patients’ experiences in the unique context of experimental HIV D+/R+ transplantation. Therefore, we developed PROMETHEUS (patient-reported measure of experimental transplants with HIV and ethics in the United States). To do so, we created a conceptual framework, drafted a pilot battery using existing and new measures related to this context, and refined it based on cognitive and pilot testing. PROMETHEUS was administered 6-months post-transplant in a clinical trial evaluating these transplants. We analyzed data from the first 20 patient-participants for reliability and validity by calculating Cronbach’s alpha and reviewing item performance characteristics.
PROMETHEUS 1.0 consisted of 29 items with 5 putative subscales: Emotions; Trust; Decision Making; Transplant; and Decision Satisfaction. Overall, responses were positive. Cronbach’s alpha was > 0.8 for all subscales except Transplant, which was 0.38. Two Transplant subscale items were removed due to poor reliability and construct validity.
We developed PROMETHEUS to systematically capture patient-reported experiences with this novel experimental transplantation program, nested it in an actual clinical trial, and obtained preliminary data regarding its performance.
People living with HIV (PLWH) are at increased risk of organ failure that is amenable to treatment with organ transplantation. However, transplant candidates living with HIV experience longer organ wait times compared to their HIV-negative (HIV-) counterparts, resulting in increased waitlist mortality [1, 2]. In effort to ameliorate this inequity, as well as to alleviate the organ shortage in general, novel transplantation of HIV-positive (HIV+) donor organs for HIV+ recipients (HIV D+/R+) is being performed [3, 4]. While early experience suggests that these transplants are safe and effective [5, 6], HIV D+/R+ transplantation raises ethical issues that must be addressed . For example, there are uncertain medical risks, such as those associated with the use of immunosuppressive agents along with antiretroviral therapy and of acquiring a second strain of HIV leading to HIV-superinfection [8, 9]. There are also psychosocial risks related to having to choose between accepting an HIV+ donor organ for which there are limited safety and efficacy data versus the burden of staying on an organ waitlist awaiting standard transplantation with one that is HIV- . Accordingly, to help assess the overall appropriateness of novel HIV D+/R+ organ transplantation, it is essential to ascertain the perspectives of patients undergoing these transplants.
There is increasing recognition of the importance of using patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) to assess the effects of interventions being evaluated in research . Similarly, PROMs and PREMs are being applied in clinical practice [11,12,13,14]. In the field of transplantation, there are existing, patient-reported measures of the informed consent process, emotions, decisional regret and trust [15,16,17,18,19,20]. However, these measures may not apply to the unique context of experimental HIV D+/R+ transplantation and do not capture the range of ethical issues raised by this novel procedure.
Therefore, we aimed to create PROMETHEUS: a patient-reported measure of experimental transplants with HIV and ethics in the United States. This article describes the development of PROMETHEUS and its preliminary performance in a large-scale national clinical trial of HIV D+/R+ renal transplantation funded by the U.S. National Institutes of Health. By including PROMETHEUS in this and other related transplant settings, we hope to facilitate a more comprehensive analysis of HIV D+/R+ transplantation. While the primary outcomes of this trial are clinical, the impact of these novel transplants on the quality of life of the patients receiving them and whether ethical issues are encountered are also critical. Without a focused assessment that captures the unique context of novel HIV D+/R+ transplantation, the rights and interests of the patients this practice intends to benefit are at risk of being overshadowed by accelerating clinical progress while the window of opportunity to implement corrected policies and practices in a systematic manner closes.
PROMETHEUS was developed as part of a larger multidisciplinary project aimed at understanding the ethical, legal and social issues associated with HIV D+/R+ transplantation. The larger project includes in-depth interviews with recipients of HIV D+/R+ transplants, potential HIV+ living donors  and independent recipient advocates  as well as a quantitative survey of transplant candidates living with HIV on the organ transplant waitlist regarding their willingness to accept HIV D+/R+ transplants .
Work to develop and test PROMETHEUS was approved by the Johns Hopkins Medicine Institutional Review Board. An overview of the development process is displayed in Fig. 1.
Concept and domain identification
The project built on early conceptual work regarding ethical issues in HIV D+/R+ transplantation by members of our project team . Specifically, emerging data from our interview and survey studies informed the development of a more comprehensive conceptual framework with relevant domains to be included in PROMETHEUS. In particular, preliminary thematic analyses of interviews with HIV D+/R+ transplant recipients at Johns Hopkins Hospital along with survey responses of transplant candidates living with HIV from nine transplant centers in the United States were incorporated into the conceptual framework. A landscape review of the literature was then conducted using PubMed to identify other potentially relevant issues reported by patients undergoing organ transplantation, experimental procedures in general, or who were in other similar clinical contexts. Items that had been used to collect patient-reported outcomes and experiences in these contexts were also ascertained as part of the literature review.
Item selection, development and cognitive testing
An initial pool of items was created by identifying the domains in our conceptual framework for which there were existing published measures and then those measures were reviewed for relevant items. New items specific to HIV D+/R+ transplantation were drafted to capture concepts and domains without existing validated scales.
Cognitive interviews regarding an initial pool of candidate items were conducted with a convenience sample of PLWH who receive medical care at the Johns Hopkins Medical Institutions. Evaluation for organ transplantation was not an inclusion criterion for these interviews, given the relatively limited patient population. At the time of the cognitive interviews, there were also too few recipients of HIV D+/R+ transplants to create an adequate sample of PLWH who had actually received a HIV D+/R+ transplant. To account for this, participants were asked to imagine that they had kidney failure and were presented with a detailed description of how kidney failure might impact their daily lives.
“Imagine that you had kidney failure. You often felt tired and sluggish. Sometimes you felt swollen up, dizzy, or out of breath. A piece of tubing had been inserted into your chest. This restricted some of your physical movement and was sometimes uncomfortable. Three times per week you had to go to the dialysis center and spend about 6 hours hooked up to a dialysis machine. You followed a strict diet: low salt, little meat, and small amounts of fluid. You decided to have a kidney transplant if a matched kidney could be found for you. After waiting for some time on the transplant list, you decided to accept an HIV+ kidney instead of waiting for an HIV- kidney so that you could get off dialysis and return to a more normal life. You had transplant surgery and got a new HIV+ kidney. You now feel pretty much how you felt before you had kidney failure, when your kidneys were still working.”
In addition, participants were informed that HIV D+/R+ transplants were experimental and that the survey being developed was going to be used in a study assessing them. Following written consent, participants were asked to evaluate individual survey items by providing their thoughts, opinions, and understanding of each question using standard cognitive interview techniques . The interviewer took notes and aggregated interview responses to write narrative accounts summarizing the cognitive interviews. The interviews lasted approximately 30 min and participants were given a $25 gift card as compensation for their time.
The results of the first round of cognitive interviews were analyzed and survey items were revised to address issues raised by participants. A second round of cognitive interviews with the revised items was conducted with a new convenience sample of PLWH.
For pilot testing, participants were again asked to imagine they had kidney failure along with a written (in contrast to the oral description used in the cognitive interviews) description of how kidney failure might impact their daily lives. Due to the limited population of patients being evaluated for these transplants, pilot testing was then conducted with a new convenience sample of PLWH who were not being evaluated for organ transplantation at the time of interview. As in the cognitive interviews, participants were informed that HIV D+/R+ transplants were experimental and that the survey being developed was going to be used in a study assessing them. Participants provided written consent. Surveys took approximately 15 min to complete and participants were given a $25 gift card as compensation for their time. Minimal revisions to survey items were made as a result of pilot testing.
Preliminary assessment of reliability
Using the data from the pilot testing, a preliminary assessment of the reliability of the putative scales and the overall battery was conducted by calculating Cronbach’s alpha using Stata 16.1. These results were used to finalize PROMETHEUS Version 1.0.
Fielding in a clinical trial
PROMETHEUS Version 1.0 is currently being fielded in a large-scale national study funded by the U.S. National Institutes of Health, which began enrollment in July 2018 (U01AI134591: HOPE in Action: A Multicenter Clinical Trial of HIV-to-HIV Deceased Donor Kidney Transplantation [NCT03500315]). In this study, PROMETHEUS is administered beginning at the 6 months post-transplant visit and then annually thereafter, through 5 years of post-transplant follow-up. The study also incorporates standard measures of health related quality of life (KDQOL-SF™ v1.3 and RAND SF-20, respectively) [25, 26] to supplement measures of ethics and related experiences being elicited by PROMETHEUS. The analysis included in this paper only includes the 6-month post-transplant responses of the first 20 participants who received an HIV D+ organ in the study.
Internal consistency reliability, construct validity and item reduction
Using the data from the initial participants in the study, an analysis of PROMETHEUS Version 1.0 was conducted to assess reliability and validity. Internal consistency reliability was estimated using Cronbach’s alpha. A Cronbach’s alpha of 0.7 or greater was considered acceptable  and item-total correlations were calculated to determine the extent to which items within the same scale measure the same construct. Construct validity was explored by examining convergent and discriminant construct validity using a multitrait-multimethod matrix. Score distributions were calculated for each item and subscale score to further examine construct validity, including mean, median, and the proportion of minimum and maximum responses to assess the floor and ceiling effects. Construct validity was further tested using the physical and mental component summary (PCS/MCS) scores of the KDQOL-36™ . Items that lacked construct validity were removed.
Concept and domain identification
Based on the preliminary content analyses of interviews with transplant recipients of HIV+ donor organs and surveys of PLWH on transplant waitlists, the following key ethics concepts were identified for inclusion in our preliminary conceptual framework: consent process, decision making, trust, emotions, impact of transplant, stigma, support, HIV status of donor, and who knows about study participation. These 9 preliminary concepts were interrogated in our landscape literature review in PubMed. Using 8 search terms in February 2017, 412 postings were identified and narrowed to 15 relevant articles based on review of titles and abstracts as well as the full article if necessary. The search term “decisional regret” and “surgery” resulted in 62 postings of which 4 were determined to be of relevance [28,29,30,31]; “consent” and “satisfaction” and “transplant” resulted in 78 postings of which 1 was determined to be of relevance ; “decision regret” [title] resulted in 27 postings of which 2 were determined to be of relevance [32, 33]; “decisional regret” [title] resulted in 14 postings of which 1 was determined to be of relevance ; “satisfaction” [title] and “consent” [title] resulted in 18 postings of which 1 was determined to be of relevance ; “evaluation of consent process” [title] resulted in 30 postings of which 1 was determined to be of relevance ; “managing expectations” and “transplant” resulted in 18 postings of which 3 were determined to be of relevance [16, 19, 20]; and “kidney transplant” and “expectations” resulted in 165 postings of which 2 were determined to be of relevance [15, 18]. In addition to the 15 articles identified through these PubMed searches, 4 articles known to members of the study team were included for review [37,38,39,40]. Together, these 19 articles described 13 tools used to collect patient-reported outcomes and experiences (Table 1).
Based on this literature review and the preliminary analyses of our interview and survey studies, 37 domains and 51 sub-domains were identified that comprised our final conceptual framework for PROMETHEUS (Table 2).
Item selection, development and cognitive testing
Domains from our conceptual framework that had existing validated measures were identified and reviewed for potential inclusion in PROMETHEUS. Six such scales were considered: the “Brief Informed Consent Evaluation Protocol” ; the “Decision Regret Scale” ; the “PROMIS Item Bank v1.0 – Emotional Distress – Anxiety – Short Form 8a” ; the “Abbreviated Wake Forest Physician Trust Scale – Patient trust in the medical profession” ; the “Revised Health Care System Distrust Scale” ; and the “Multidimensional Trust in Health Care Systems Scale” .
An initial pool of 25 relevant items was selected from these 6 existing scales. Three out of 12 items were selected from the “Brief Informed Consent Evaluation Protocol” (BICEP)  to cover consent process domains. All 5 items from the “Decision Regret Scale”  were selected to measure decisional regret. All 8 items from the “PROMIS Item Bank v1.0 – Emotional Distress – Anxiety – Short Form 8a” (PROMIS Anxiety SF 8a)  were selected to cover impact of transplant and emotions domains. All 5 items from the “Abbreviated Wake Forest Physician Trust Scale – Patient trust in the medical profession” (A-WFPT Scale)  were selected to cover trust. Three out of 9 items were selected from the “Revised Health Care System Distrust Scale” (R-HCSD Scale)  to cover trust and stigma domains. Finally, 1 out of 17 items were selected from the “Multidimensional Trust in Health Care Systems Scale” (MTHCS Scale)  to cover the domain of trust in institutions. These 25 questions encompass 11 out of 37 domains and 5 out of 9 concepts from our conceptual framework (Table 2).
The following 10 key domains were then identified as not having existing validated scales: vulnerability, reasons to accept an HIV D+ organ, discuss/consult study participation, trust in medical research in the context of these transplants, feeling unprepared for transplant, stigma related to HIV status, stigma related to race/ethnicity, support from the medical team, support from the research team, and the perception that a false-positive (i.e., a donor organ that was initially assumed to be from an HIV+ donor based on initial testing at the time a transplant decision was being made, but was subsequently found not to be HIV+) or HIV- organ is better than an HIV+ organ. Accordingly, 8 experimental items specific to HIV D+/R+ transplantation were drafted, resulting in a preliminary pool of 33 items. This preliminary pool of 33 items was then grouped into 5 subscales: A – Decision Making and Consent, B – Decisional Regret, C – Anxiety, D – Trust in Medical Care, and E – HIV+ Transplant Experience (our experimental items). In doing so, the project team reached consensus that all essential aspects of our conceptual framework for PROMETHEUS were addressed by these items.
In the first round of cognitive interviews with 7 PLWH, all participants self-identified as Black/African American and 4 self-identified as female. Two participants were 35–44 years old, 2 were 45–54 years old, and 3 were 55–64 years old. Two participants had less than a high school education, 4 graduated from high school or received their Graduate Equivalent Degree, and 1 had a bachelor’s degree.
As a result of these interviews, the orderings of the subscales were adjusted, some items were modified and others deleted. Specifically subscale A – “Decision Making and Consent” was moved to be the third subscale and all 3 questions were changed to statements rather than questions so that the response options could be on a 5 point Likert-type scale from Never to Always. Subscale B – “Decisional Regret” was moved to be the last subscale. Subscale C – “Anxiety” was moved to be the first subscale. Subscale D – “Trust in Medical Care” was moved to be the second subscale and the question from the MTHCS Scale (“Health care institutions provide the highest quality in medical care”) was removed due to respondent confusion regarding what a health care institution was and their uncertainty regarding how to interpret “highest quality in medical care.” Despite removing this item, the concept of trust seemed to be sufficiently covered by the domains trust in medicine and trust in medical research.
For Subscale E – “HIV+ Transplant Experience”, 2 out of 8 items were removed and wording changes were made to 5 items. The HIV+ Transplant Experience subscale was also moved to be the penultimate subscale. The fourth item, “I was relieved to learn that I got an HIV negative organ and not one that was HIV positive” was removed because all but one respondent indicated that they strongly agree because taking an HIV+ donor organ is a risk, makes transplantation complicated, and might not work as well. The item, “This study makes me feel like my HIV diagnosis gives me the unique ability to help others” was removed because it was unclear and the domain of stigma due to HIV status was adequately captured by 2 other items (“Because of my HIV status, joining this study was the best chance I had at getting a transplant” and “Being a part of this study made me feel better about having HIV”, respectively). The item, “Trust in the healthcare workers on the study team was a significant factor in my decision to participate” was modified to, “Trust in doctors and nurses who took care of me was a significant factor in my decision to get a new organ” due to respondents’ inaccurate belief that “study team” meant people studying to become doctors. Another was simplified from, “When I was told there was an organ available for me I felt pressure to accept it” to, “When I was told there was an organ for me, I felt pressure to accept it”. Two other items (“Because of my race, joining this study was the best chance I had at getting a transplant”; and “Because of my HIV status, joining this study was the best chance I had at getting a transplant”, respectively) were modified to, “Because of my race, accepting this organ was the best chance I had at getting a transplant”; and “Because of my HIV status, accepting this organ was the best chance I had at getting a transplant” to clarify what “joining this study” meant. “Being a part of this study made me feel better about having HIV” was also modified to, “Being able to get this transplant made me feel better about having HIV” to omit confusion over what “this study” was referring to.
As a result of these changes, 30 items were included in the following subscales: Section A – Anxiety, Section B – Trust in Medical Care, Section C – Decision Making and Consent, Section D – HIV+ Transplant Experience, Section E – Decisional Regret.
A second round of cognitive interviews was conducted with 5 PLWH to get feedback on the revised 30 items and their ordering. Four participants self-identified as Black/African American and 1 self-identified as White, Black, and Puerto Rican. One out of 5 participants self-identified as female, 1 was 45–54 years old, and the remaining 4 were 55–64 years old. Three participants had less than a high school education, and the remaining 2 had graduated from high school or received their Graduate Equivalent Degree. Analysis of the second round of cognitive interviews found that no further edits to survey items were needed prior to pilot testing.
The 30 item pilot survey was then administered to 20 participants. Seventeen self-identified as Black/African American and 3 self-identified as American Indian/Alaska Native. Eleven participants were female, 2 were 25–34 years old, 4 were 35–44 years old, 6 were 45–54 years old, and 8 were 55–64 years old. Seven participants had less than a high school education, 10 graduated from high school or received their Graduate Equivalent Degree, 2 had a bachelor’s degree, and 1 had a graduate degree. As a result of pilot testing, 1 item was removed from the HIV+ Transplant Experience subscale (“When I was told there was an organ for me, I felt pressure to accept it”) since the domain of vulnerability during the consent process was adequately captured by an item in the Decision Making subscale (“I felt pressure to accept the new organ”).
Initial reliability testing
Cronbach’s alpha for all items was 0.89. For the putative subscales this value was: Emotions = 0.93; Trust = 0.82; Decision Making = 0.57; Transplant = 0.59; and Decision Satisfaction = 0.71. Based on this performance in a hypothetical setting, no further refinements were made to the battery.
Fielding in a clinical trial
The final battery (See Additional file 1: PROMETHEUS Fielded Battery) was then prepared for fielding in the national trial described above. A cover page included the following instructions: “This survey includes a wide variety of questions related to how you are feeling and the decisions you made regarding the possibility of receiving an HIV+ donor organ” and, “Directions: Please circle the one response that BEST describes your answer to the question”. The 29 item PROMETHEUS Version 1.0 consisted of 5 subscales: Section A – Emotions (8 items), Section B –Trust (8 items); Section C – Decision Making (3 items); Section D – Transplant (5 items), Section E – Decision Satisfaction (5 items). Section A – Emotions (rather than being termed Anxiety to be more neutral) gave instruction to consider the past 7 days only (“In the past 7 days …” ) and response options were given as a 5 point Likert-type scale from Never to Always. The rest of the sections gave response options as a 5 point Likert scale from Strongly Agree to Strongly Disagree. Section E – Decision Satisfaction, instructed that, “The next set of questions are about your decision to get the new organ”. A section to be completed by the study team at end of the battery queried how PROMETHEUS was completed (“Self-administered by patient” vs. “In-person interview” vs. “Telephone interview” vs. “Other; specify”) and if it was completed by direct data entry.
Evaluation in the target population and item reduction
The first 20 trial participants had a median age of 53 years (IQR: 45–58); 20% were female; 75% identified as Black/African American and 10% identified as Asian; none identified as Latino/Hispanic (Table 3).
Internal consistency was acceptable for the Emotions, Trust, Decision, and Satisfaction scales (Cronbach’s alpha > 0.8) (Table 4). The 5 HIV+ Transplant Experience subscale items (Section D – Transplant) were analyzed as independent items due to poor internal consistency (Cronbach’s alpha for all 5 items = .38). Based on this evaluation and concerns about construct validity, 2 items were removed from the HIV+ Transplant Experience subscale. Specifically, item D1, “My recovery was harder than I imagined” was removed since its connection to ethics concerns was unclear; and item D3, “Because of my race, accepting this organ was the best chance I had at getting a transplant” because it’s hypothesized relationship would only be true for racial minority respondents and uninterpretable for others.
In general, the scale scores are right skewed. Distribution of the Emotions, Trust, Decision, and Satisfaction scales and the Transplantation items are shown in Table 4. Each multi-item scale’s internal consistency coefficient exceeded its correlations with other scales, as well as with the Physical Component Summary (PCS) and Mental Component Summary (MCS) scores of the KDQOL-36™ , administered at the 6-months post-transplant visit. PCS was negatively correlated with all multi-item scales. As expected, MCS had a stronger correlation with the Emotions scale (correlation coefficient: − 0.80) and weak correlation with other scales (Table 5).
To be able to garner a more comprehensive assessment regarding the ethical aspects of experimental HIV D+/R+ transplantation, we developed an exploratory ethics summary score comprised of the scores of the Trust in Medical Care, Decision Making and Consent, and Decisional Regret subscales. Scoring of particular items was reversed where necessary so that all were uniform in terms of potentially problematic responses. Participants received 1 point for each scale where they scored in the upper quartile. The sum of the points from each scale make up the overall score, with a score of 0 indicating no ethical flag and a score of 3 indicating the highest possible ethical flag. Among the 20 participants, 55% had a score of 0, 15% had a score of 1, 20% had a score of 2, and 10% had a score of 3.
Overall, members of the first cohort of participants enrolled in a large nationwide clinical trial of HIV D+/R+ renal transplantation generally reported positive experiences regarding salient ethics domains related to their participation (Table 4). In particular, 6 months following their experimental transplants, participants commonly reported favorable experiences with the decision-making and consent process to accept an HIV D+ organ (based on an aggregate score of having enough information, not feeling pressure, and being satisfied with the consent process). Further, recipients tended to be neutral regarding whether accepting the HIV D+ organ provided their best chance of getting a transplant given their HIV+ status, perhaps suggesting that they were not pressured to make an unwelcome choice based on their perception of organ availability and access to a life-sustaining intervention. As a related matter, despite the uncertain risks at the time they gave consent to receive an HIV D+ organ, preliminary data suggest that recipients were generally satisfied with their decision to accept an HIV D+ organ and were doing well emotionally following their transplants. Recipients also reported substantial trust, which is consistent with their having agreed to participate in a study evaluating experimental transplants. Finally, participants tended to agree that their HIV D+/R+ transplant made them feel better about living with HIV. This finding is salutary given the stigma that is associated with HIV.
While each of the ethics domains and selected items in the PROMETHEUS battery provide important insight into the experiences of recipients of experimental HIV D+/R+ transplants, we explored the possibility of creating a preliminary summary ethics score to provide an overarching impression of these novel transplants. Overall, the summary ethics score was sanguine with a median of 0, although 2 participants had a score of 3. Nevertheless, to date, patient-participants have not reported substantial ethics concerns with the conduct of the trial. However, this and the generally positive reported experiences in regard to key ethics domains and items may not be surprising given that participants had survived a life-changing transplant by the time they completed the battery.
Nevertheless, in interpreting these preliminary findings it is important to recognize that these data come from a small number of patient-participants in the context of a single carefully conducted clinical trial. The small sample size unfortunately precludes conducting robust psychometric evaluations of PROMETHEUS, such as exploratory factor analyses. In addition, since the data derive from one high-profile clinical trial, the data may not be generalizable to other settings. Regardless, this is the largest available cohort to date of patients undergoing experimental HIV D+/R+ renal transplants in the United States. In the future, it will be essential to evaluate emerging data from this and other related transplant trials, not only to provide further evidence for the validity of PROMETHEUS through the conduct of proper psychometric analyses, but also to identify any potential ethics concerns that may arise.
As the battery is used in clinical transplantation trials, investigators, Institutional Review Boards, and Data Safety and Monitoring Boards may want to use responses to some or all PROMETHEUS scales or items to trigger action on the part of research teams. To accomplish this, future studies should determine how to interpret scores on PROMETHEUS, including its performance as a screening tool to identify potential ethical issues. Such an approach could provide additional protection of research participants.
We used a rigorous, patient centered approach to develop PROMETHEUS, a battery of measures to interrogate patients’ experiences concerning the ethical issues associated with this novel field of HIV D+/R+ transplantation. By nesting PROMETHEUS within a large clinical trial, we were able to provide preliminary data on its performance, and also to demonstrate the feasibility of nesting an ethics-related patient measure in such transplantation trials.
Availability of data and materials
The datasets used and analyzed in developing PROMETHEUS are available from the corresponding author on reasonable request.
- HIV D+/R +:
HIV-positive donor organs for HIV+ recipients
Mental Component Summary
Physical Component Summary
People living with HIV
- PROMETHEUS :
Patient-Reported Measure of Experimental Transplants with HIV and Ethics in the United States
Cohen, J. B., Locke, J. E., Shelton, B., Reed, R. D., Mustian, M., MacLennan, P., … Sawinski, D. (2019). Disparity in access to kidney allograft offers among transplant candidates with human immunodeficiency virus. Clinical Transplantation, 33(2), e13466. https://doi.org/10.1111/ctr.13466 Epub 2019 Jan 12. PMID: 30578590; PMCID: PMC6386602.
Tourret, J., Guiguet, M., Lassalle, M., Grabar, S., Lièvre, L., Isnard-Bagnis, C., … Tézenas Du Montcel, S. (2019). Access to the waiting list and to kidney transplantation for people living with HIV: A national registry study. American Journal of Transplantation, 19(12), 3345–3355. https://doi.org/10.1111/ajt.15500 Epub 2019 Aug 1. PMID: 31206243.
Boyarsky, B. J., & Segev, D. L. (2016). From bench to bill: How a transplant nuance became 1 of only 57 laws passed in 2013. Annals of Surgery, 263(3), 430–433. https://doi.org/10.1097/SLA.0000000000001352 PMID: 26575282.
Malani, P. (2016). HIV and transplantation: New reasons for HOPE. JAMA, 316(2), 136–138. https://doi.org/10.1001/jama.2016.8158 PMID: 27404170.
Muller, E., Barday, Z., Mendelson, M., & Kahn, D. (2015). HIV-positive-to-HIV-positive kidney transplantation--results at 3 to 5 years. The New England Journal of Medicine, 372(7), 613–620. https://doi.org/10.1056/NEJMoa1408896 PMID: 25671253; PMCID: PMC5090019.
Selhorst, P., Combrinck, C. E., Manning, K., Botha, F. C. J., Labuschagne, J. P. L., Anthony, C., … Muller, E. (2019). Longer-term outcomes of HIV-positive-to-HIV-positive renal transplantation. The New England Journal of Medicine, 381(14), 1387–1389. https://doi.org/10.1056/NEJMc1903013 PMID: 31577883.
Durand, C. M., Segev, D., & Sugarman, J. (2016). Realizing HOPE: the ethics of organ transplantation from HIV-positive donors. Annals of Internal Medicine, 165(2), 138–142. https://doi.org/10.7326/M16-0560 Epub 2016 Apr 5. PMID: 27043422; PMCID: PMC4949150.
Boyarsky, B. J., Durand, C. M., Palella Jr., F. J., & Segev, D. L. (2015). Challenges and clinical decision-making in HIV-to-HIV transplantation: Insights from the HIV literature. American Journal of Transplantation, 15(8), 2023–2030. https://doi.org/10.1111/ajt.13344 Epub 2015 Jun 16. PMID: 26080612.
Redd, A. D., Quinn, T. C., & Tobian, A. A. (2013). Frequency and implications of HIV superinfection. The Lancet Infectious Diseases, 13(7), 622–628. https://doi.org/10.1016/S1473-3099(13)70066-5 Epub 2013 May 31. PMID: 23726798; PMCID: PMC3752600.
U.S. Department of Health and Human Services, Food and Drug Administration (2009). Guidance for industry of patient-reported outcome measures: Use in medical product development to support labeling claims. Federal Register, 74(235), 65132–65133.
Brundage, M. D., Wu, A. W., Rivera, Y. M., & Snyder, C. (2020). Promoting effective use of patient-reported outcomes in clinical practice: Themes from a “methods tool kit” paper series. Journal of Clinical Epidemiology, 122, 153–159. https://doi.org/10.1016/j.jclinepi.2020.01.022 Epub 2020 Feb 13. PMID: 32061828.
Rotenstein, L. S., Huckman, R. S., & Wagle, N. W. (2017). Making patients and doctors happier - the potential of patient-reported outcomes. The New England Journal of Medicine, 377(14), 1309–1312. https://doi.org/10.1056/NEJMp1707537 PMID: 28976860.
Baumhauer, J. F. (2017). Patient-reported outcomes - are they living up to their potential? The New England Journal of Medicine, 377(1), 6–9. https://doi.org/10.1056/NEJMp1702978 PMID: 28679102.
Basch, E. (2017). Patient-reported outcomes - harnessing patients’ voices to improve clinical care. The New England Journal of Medicine, 376(2), 105–108. https://doi.org/10.1056/NEJMp1611252 PMID: 28076708.
Cleemput, I., Kesteloot, K., De Geest, S., Dobbels, F., & Vanrenterghem, Y. (2003). Health professionals’ perceptions of health status after renal transplantation: A comparison with transplantation candidates’ expectations. Transplantation, 76(1), 176–182. https://doi.org/10.1097/01.TP.0000072807.46212.FA PMID: 12865806.
Crawford, K., Low, J. K., Manias, E., & Williams, A. (2017). Healthcare professionals can assist patients with managing post-kidney transplant expectations. Research in Social & Administrative Pharmacy, 13(6), 1204–1207. https://doi.org/10.1016/j.sapharm.2016.11.013 Epub 2016 Dec 2. PMID: 27955977.
Little, M., Jordens, C. F., McGrath, C., Montgomery, K., Lipworth, W., & Kerridge, I. (2008). Informed consent and medical ordeal: A qualitative study. Internal Medicine Journal, 38(8), 624–628. https://doi.org/10.1111/j.1445-5994.2008.01700.x PMID: 18808560.
Schulz, T., Niesing, J., Homan van der Heide, J. J., Westerhuis, R., Ploeg, R. J., & Ranchor, A. V. (2014). Great expectations? Pre-transplant quality of life expectations and distress after kidney transplantation: A prospective study. British Journal of Health Psychology, 19(4), 823–838. https://doi.org/10.1111/bjhp.12081 Epub 2013 Dec 12. PMID: 24330416.
Speight, J., Woodcock, A. J., Reaney, M. D., Amiel, S. A., Johnson, P., Parrott, N., … Shaw, J. A. (2016). Well, I wouldn't be any worse off, would I, than I am now? A qualitative study of decision-making, hopes, and realities of adults with Type 1 Diabetes undergoing islet cell transplantation. Transplantation direct, 2(5), e72. https://doi.org/10.1097/TXD.0000000000000581 PMID: 27500262; PMCID: PMC4946514.
Tong, A., Hanson, C. S., Chapman, J. R., Halleck, F., Budde, K., Josephson, M. A., & Craig, J. C. (2015). ‘Suspended in a paradox’-patient attitudes to wait-listing for kidney transplantation: Systematic review and thematic synthesis of qualitative studies. Transplant International, 28(7), 771–787. https://doi.org/10.1111/tri.12575 Epub 2015 Apr 20. PMID: 25847569.
Van Pilsum Rasmussen, S. E., Henderson, M. L., Bollinger, J., Seaman, S., Brown, D., Durand, C. M., … Sugarman, J. (2018). Perceptions, motivations, and concerns about living organ donation among people living with HIV. AIDS Care, 30(12), 1595–1599. https://doi.org/10.1080/09540121.2018.1469724 Epub 2018 May 3. PMID: 29724118; PMCID: PMC6206869.
Bollinger, J. M., Eno, A., Seaman, S., Brown, D., Van Pilsum Rasmussen, S. E., Tobian, A. A. R., … Sugarman, J. (2019). Early experiences of independent advocates for potential HIV+ recipients of HIV+ donor organ transplants. Clinical Transplantation, 33(7), e13617. https://doi.org/10.1111/ctr.13617 Epub 2019 Jun 19. PMID: 31140611; PMCID: PMC6779050.
Seaman, S. M., Van Pilsum Rasmussen, S. E., Nguyen, A. Q., Halpern, S. E., You, S., Waldram, M. M., … Durand, C. M. (2020). Brief Report: Willingness to accept HIV-infected and increased Infectious Risk Donor organs among transplant candidates living with HIV. Journal of Acquired Immune Deficiency Syndromes, 85(1), 88–92. https://doi.org/10.1097/QAI.0000000000002405 PMID: 32427721; PMCID: PMC7429320.
Willis, G. B. (2005). Cognitive interviewing: A tool for improving questionnaire design, (375 p). Thousand Oaks: Sage.
Hays, R. D., Kallich, J. D., Mapes, D. L., Coons, S. J., Amin, N., & Carter, W. B. (1995). Kidney disease quality of life short form (KDQOL-SFTM), version 1.3: A manual for use and scoring. Santa Monica: RAND, Document P-7994.
Ware, J. E., Sherbourne, C. D., & Davies, A. R. (1992). Developing and testing the MOS 20-item short-form health survey: A general population application. In A. L. Stewart, & J. E. Ware (Eds.), Measuring functioning and well-being: The medical outcomes study approach, (pp. 277–290). Durham: Duke University Press.
Nunnally, J. C. (1978). Psychometric theory, (2nd ed., 736 p). New York: McGraw-Hill.
Davison, B. J., & Goldenberg, S. L. (2003). Decisional regret and quality of life after participating in medical decision-making for early-stage prostate cancer. BJU International, 91(1), 14–17. https://doi.org/10.1046/j.1464-410x.2003.04005.x PMID: 12614242.
Gordon, E. J., Mullee, J., Butt, Z., Kang, J., & Baker, T. (2015). Optimizing informed consent in living liver donors: Evaluation of a comprehension assessment tool. Liver Transplantation, 21(10), 1270–1279. https://doi.org/10.1002/lt.24175 PMID: 25990592.
Hanson, C. S., Chadban, S. J., Chapman, J. R., Craig, J. C., Wong, G., Ralph, A. F., & Tong, A. (2015). The expectations and attitudes of patients with chronic kidney disease toward living kidney donor transplantation: A thematic synthesis of qualitative studies. Transplantation, 99(3), 540–554. https://doi.org/10.1097/TP.0000000000000433 PMID: 25463967.
Steffens, N. M., Tucholka, J. L., Nabozny, M. J., Schmick, A. E., Brasel, K. J., & Schwarze, M. L. (2016). Engaging patients, health care professionals, and community members to improve preoperative decision making for older adults facing high-risk surgery. JAMA, 151(10), 938–945. https://doi.org/10.1001/jamasurg.2016.1308 PMID: 27368074.
Becerra Pérez, M. M., Menear, M., Brehaut, J. C., & Légaré, F. (2016). Extent and predictors of decision regret about health care decisions: A systematic review. Medical Decision Making, 36(6), 777–790. https://doi.org/10.1177/0272989X16636113 Epub 2016 Mar 14. PMID: 26975351.
Nicolai, J., Buchholz, A., Seefried, N., Reuter, K., Härter, M., Eich, W., & Bieber, C. (2016). When do cancer patients regret their treatment decision? A path analysis of the influence of clinicians’ communication styles and the match of decision-making styles on decision regret. Patient Education and Counseling, 99(5), 739–746. https://doi.org/10.1016/j.pec.2015.11.019 Epub 2015 Dec 2. PMID: 26658703.
Wilson, A., Winner, M., Yahanda, A., Andreatos, N., Ronnekleiv-Kelly, S., & Pawlik, T. M. (2017). Factors associated with decisional regret among patients undergoing major thoracic and abdominal operations. Surgery, 161(4), 1058–1066. https://doi.org/10.1016/j.surg.2016.10.028 Epub 2016 Dec 16. PMID: 27993362.
Goldberger, J. J., Kruse, J., Kadish, A. H., Passman, R., & Bergner, D. W. (2011). Effect of informed consent format on patient anxiety, knowledge, and satisfaction. American Heart Journal, 162(4), 780–785.e1. https://doi.org/10.1016/j.ahj.2011.07.006 Epub 2011 Sep 14. PMID: 21982673.
Uzzaman, M. M., Sinha, S., Shaygi, B., Vitish-Sharma, P., Loizides, S., & Myint, F. (2012). Evaluation of patient's understanding and recall of the consent process after open inguinal hernia repairs. International Journal of Surgery, 10(1), 5–10. https://doi.org/10.1016/j.ijsu.2011.10.003 Epub 2011 Oct 25. PMID: 22051351.
Hall, M. A., Camacho, F., Lawlor, J. S., Depuy, V., Sugarman, J., & Weinfurt, K. (2006). Measuring trust in medical researchers. Medical Care, 44(11), 1048–1053. https://doi.org/10.1097/01.mlr.0000228023.37087.cb PMID: 17063137.
Joffe, S., Cook, E. F., Cleary, P. D., Clark, J. W., & Weeks, J. C. (2001). Quality of informed consent in cancer clinical trials: A cross-sectional survey. Lancet, 358(9295), 1772–1777. https://doi.org/10.1016/S0140-6736(01)06805-2 PMID: 11734235.
Kass, N., Faden, R., Fabi, R. E., Morain, S., Hallez, K., Whicher, D., … Pitcavage, J. (2016). Alternative consent models for comparative effectiveness studies: Views of patients from two institutions. AJOB Empirical Bioethics, 7(2), 92–105.
Sugarman, J., Lavori, P. W., Boeger, M., Cain, C., Edsond, R., Morrison, V., & Yeh, S. S. (2005). Evaluating the quality of informed consent. Clinical Trials, 2(1), 34–41. https://doi.org/10.1191/1740774505cn066oa PMID: 16279577.
O’Connor, A. M. (1996). User manual – Decision regret scale [internet]. Ottawa: Ottawa Hospital Research Institute [updated 2003; cited 2020]. Available from: www.ohri.ca/decisionaid.
PROMIS Item Bank v1.0 – Emotional Distress – Anxiety – Short Form 8a. Investigator Format PROMIS Health Organization and PROMIS Cooperative Group; 2008–2016. Available from: https://www.healthmeasures.net/index.php. [cited 2020].
Dugan, E., Trachtenberg, F., & Hall, M. A. (2005). Development of abbreviated measures to assess patient trust in a physician, a health insurer, and the medical profession. BMC Health Services Research, 5, 64. https://doi.org/10.1186/1472-6963-5-64 PMID: 16202125; PMCID: PMC1262715.
Shea, J. A., Micco, E., Dean, L. T., McMurphy, S., Schwartz, J. S., & Armstrong, K. (2008). Development of a revised Health Care System Distrust scale. Journal of General Internal Medicine, 23(6), 727–732. https://doi.org/10.1007/s11606-008-0575-3 Epub 2008 Mar 28. PMID: 18369678; PMCID: PMC2517896.
Egede, L. E., & Ellis, C. (2008). Development and testing of the Multidimensional Trust in Health Care Systems Scale. Journal of General Internal Medicine, 23(6), 808–815. https://doi.org/10.1007/s11606-008-0613-1 Epub 2008 Apr 16. PMID: 18415653; PMCID: PMC2517872.
The authors thank the participants of the HOPE in Action study and the HOPE in Action study team. The comments of the peer-reviewers on an earlier version of this manuscript helped to improve it.
This work was supported by The Greenwall Foundation Making a Difference grant (Sugarman), grant numbers 1P30AI094189 (Johns Hopkins Center for AIDS Research), 1R01AI120938 (Tobian), U01AI134591 (Durand/Segev), and U01AI138897 (Durand/Segev) from the National Institute of Allergy and Infectious Diseases, grant number K23CA177321-01A1 (Durand) from the National Cancer Institute, and grant numbers K24DK101828 (Segev) and K01DK101677 (Massie) from the National Institute of Diabetes and Digestive and Kidney Diseases. The analyses described here are the responsibility of the authors alone and do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the U.S. Government.
Ethics approval and consent to participate
Work to develop and test PROMETHEUS was approved by the Johns Hopkins Medicine Institutional Review Board [IRB00151494]. Written informed consent was obtained for cognitive and pilot testing.
Consent for publication
Christine M. Durand has received grant support from Abbvie and GlaxoSmithKline. She serves on a grant review committee for Gilead Sciences. Jeremy Sugarman is a member of Merck KGaA’s Bioethics Advisory Panel and Stem Cell Research Oversight Committee, a member of IQVIA’s Ethics Advisory Panel, a member of Aspen Neurosciences Scientific Advisory Board, consults with Biogen, and has consulted with Portola Pharmaceuticals, Inc., unrelated to the data described in this manuscript. All other authors report no conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Seaman, S., Brown, D., Eno, A. et al. Development of a Patient Reported Measure of Experimental Transplants with HIV and Ethics in the United States (PROMETHEUS). J Patient Rep Outcomes 5, 28 (2021). https://doi.org/10.1186/s41687-021-00297-y
- Acquired immunodeficiency syndrome
- Care delivery
- Organ procurement and transplantation
- Patient-reported experiences
- Patient safety
- Quality of care